These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 25373709)

  • 1. High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer.
    Chen Y; Xing P; Chen Y; Zou L; Zhang Y; Li F; Lu X
    World J Surg Oncol; 2014 Nov; 12():328. PubMed ID: 25373709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiRNA-200a expression is inverse correlation with hepatocyte growth factor expression in stromal fibroblasts and its high expression predicts a good prognosis in patients with non-small cell lung cancer.
    Chen Y; Du M; Wang J; Xing P; Zhang Y; Li F; Lu X
    Oncotarget; 2016 Jul; 7(30):48432-48442. PubMed ID: 27374174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
    Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
    J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD10 expression in epithelial and stromal cells of non-small cell lung carcinoma (NSCLC): a clinic and pathologic correlation.
    Gürel D; Kargı A; Karaman I; Onen A; Unlü M
    Pathol Oncol Res; 2012 Apr; 18(2):153-60. PubMed ID: 21681600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer.
    Zhou L; Yu L; Wu S; Feng Z; Song W; Gong X
    World J Surg Oncol; 2015 Aug; 13():234. PubMed ID: 26231404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.
    Jacobsen B; Muley T; Meister M; Dienemann H; Christensen IJ; Santoni-Rugiu E; Lærum OD; Ploug M
    J Thorac Oncol; 2013 Feb; 8(2):152-60. PubMed ID: 23287851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of COX-2 in non-small cell lung cancer: a comprehensive compartment-specific evaluation of tumor and stromal cell expression.
    Mattsson JS; Bergman B; Grinberg M; Edlund K; Marincevic M; Jirström K; Pontén F; Hengstler JG; Rahnenführer J; Karlsson MG; Karlsson C; Helenius G; Botling J; Micke P; Gulyas M
    Cancer Lett; 2015 Jan; 356(2 Pt B):837-45. PubMed ID: 25449785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
    Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
    J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer.
    Dhillon T; Mauri FA; Bellezza G; Cagini L; Barbareschi M; North BV; Seckl MJ
    J Thorac Oncol; 2010 Mar; 5(3):314-9. PubMed ID: 20093977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycomb group oncogene RING1 is over-expressed in non-small cell lung cancer.
    Zhou Y; Wan C; Liu Y; Lv L; Chen B; Ni R; Huang Y; Li Y; Zheng X; Yang D; Mao G; Xue Q
    Pathol Oncol Res; 2014 Jul; 20(3):549-56. PubMed ID: 24414991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC.
    Oliemuller E; Peláez R; Garasa S; Pajares MJ; Agorreta J; Pío R; Montuenga LM; Teijeira A; Llanos S; Rouzaut A
    Int J Cancer; 2013 May; 132(9):1986-95. PubMed ID: 23023514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
    Tsoukalas N; Aravantinou-Fatorou E; Tolia M; Giaginis C; Galanopoulos M; Kiakou M; Kostakis ID; Dana E; Vamvakaris I; Korogiannos A; Tsiambas E; Salemis N; Kyrgias G; Karameris A; Theocharis S
    Anticancer Res; 2017 Apr; 37(4):1773-1778. PubMed ID: 28373440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of IGF1R expression in non-small-cell lung cancer.
    Nakagawa M; Uramoto H; Oka S; Chikaishi Y; Iwanami T; Shimokawa H; So T; Hanagiri T; Tanaka F
    Clin Lung Cancer; 2012 Mar; 13(2):136-42. PubMed ID: 22133293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.
    Donnem T; Al-Shibli K; Al-Saad S; Busund LT; Bremnes RM
    J Thorac Oncol; 2009 May; 4(5):578-85. PubMed ID: 19318994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
    Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
    J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serpin b3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer.
    Urquhart G; Kerr KM; Nicolson M; Loo PS; Sharma R; Shrimali R; Petty RD
    J Thorac Oncol; 2013 Dec; 8(12):1502-9. PubMed ID: 24389432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer in the U.S. National Cancer Data Base.
    Osarogiagbon RU; Lin CC; Smeltzer MP; Jemal A
    J Thorac Oncol; 2016 Jan; 11(1):e5-16. PubMed ID: 26762752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.